HIMS ends compounded Semaglutide offering

With the recent announcement of Semaglutide leaving the FDA shortage list:

Semaglutide removed from shortage list

It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.

GLP1 GuideGLP1.Guide Staff

Companies are already starting to change their offering with regards to compounded GLP1 Receptor Agonists.

HIMS has announced that they will ultimately stop offering compounded Semaglutide to their customers.

HIMS began selling compounded Semaglutide only in May 2024, so not even a year has passed before they began offering compounded GLP1s.

What will HIMS offer instead?

It's not clear exactly what HIMS will do instead, but it is clear that neither compounded Tirzepatide or Semaglutide are viable options.

HIMS have already announced their intent to start selling compounded Liraglutide :

HIMS to offer Liraglutide after shortage rule changes

HIMS leans into Liraglutide as a replacement for Semaglutide in the face of shortage rule changes. Is it good enough?

GLP1 GuideGLP1.Guide Staff

Liraglutide has come out from under patent protection and is currently being produced by two large pharmaceutical companies (TEVA and Hikma Pharmaceuticals):

Victoza Generic GLP1 launched by Teva Pharmaceuticals

Teva Pharmaceuticals has started manufacturing a Victoza generic drug (liraglutide), and it’s available inside the United States.

GLP1 GuideGLP1.Guide Staff

Another Generic Liraglutide launch: Hikma Phamaceuticals

A new player enters the generic GLP1 market - Hikma Pharmaceuticals. As the second generic Liraglutide provider, accessibility of GLP1s has never been better.

GLP1 GuideGLP1.Guide Staff